Researchers from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) and local biotechnology company Intra-ImmuSG have announced promising outcomes from a Phase II clinical trial of a novel cancer immunotherapy, PRL3-zumab. Published in Cell Reports Medicine, the study shows PRL3-zumab safely slows disease progression in patients with advanced solid cancers unresponsive to existing treatments.

POSTN is a valuable serum biomarker for IPF and has the highest sensitivity and specificity among the four serum markers, with a diagnostic performance superior to that of KL-6, SP-A, and SP-D. DLCO%pred and KL-6 have high predictive value for AE-IPF.

Intermountain Health cardiovascular clinician and researcher Viet Le, DMSc, MPAS, PA-C, FACC, will serve as the next editor of the American College of Cardiology’s CardioSmart program. Le is the first non-physician leader of the program.

Researchers looked at PFAS serum concentrations in health care workers for the first time and were surprised by what they found.

Brain metastases often occur as a result of advanced cancer and, despite medical innovations, are still associated with a poor prognosis. Now, an international expert committee led by the Medical University of Vienna and the Ludwig Maximilian University Hospital (LMU) in Munich has taken an important step towards improving diagnostics and therapy monitoring. A special imaging procedure, amino acid PET, can not only improve patient care, but also advance research into the development of new treatment approaches. The first standardised criteria for the use of this method have now been published in the top journal Nature Medicine.